Tesamorelin / Ipamorelin / MOTS-C
Combines two peptides that stimulate growth hormone release with MOTS-C, a mitochondrial peptide studied in metabolism. Evidence for the three-part combination is limited.
What to expect
This combination brings together ingredients studied through different pathways. Research on an individual ingredient does not establish the results or safety of combining all three, so the consultation starts with your goals and the available evidence.
- Tesamorelin acts on the growth hormone releasing hormone pathway
- Ipamorelin has stimulated growth hormone release in short human studies; that does not establish long-term benefits for this blend
- MOTS-C research includes cellular and animal studies of metabolism, which cannot predict clinical results
- Your provider reviews established treatment alternatives before discussing whether this combination is appropriate
Provider note: FDA has identified compounding safety concerns for ipamorelin and MOTS-C, including potential immune reactions and gaps in human safety information.
Monthly treatment pricing is in addition to the visit fee. Office and telehealth visits are $100.
Understanding the three ingredients
Each ingredient has a different research history. The findings are not interchangeable.
| Option | What it means |
|---|---|
| Tesamorelin | An approved tesamorelin product treats excess abdominal fat in adults with HIV-associated lipodystrophy. It is not approved for general weight loss. |
| Ipamorelin | Human research has measured growth hormone responses. It does not establish the safety or effectiveness of this three-ingredient combination. |
| MOTS-C | A mitochondrial peptide investigated in metabolic research. Animal findings are not proof of benefits from treatment in people. |
Provider note: The approval of a specific tesamorelin product does not extend to this combination.
What we go over together
- Your health history, current medications, symptoms, and the reason you are considering treatment
- Diabetes, cancer history, pituitary conditions, and whether pregnancy or breastfeeding affects your options
- Whether glucose and IGF-1 monitoring is relevant to the proposed plan
- The limits of the evidence and alternatives with better established benefits
What a listing means
This information is educational and does not establish that a medication treats, cures, or prevents a disease. Availability depends on clinical appropriateness and provider judgment, and a consultation does not guarantee a prescription.
Before treatment
Before any treatment, your provider and dispensing pharmacist must confirm the exact formulation, route, availability, and applicable prescribing and compounding requirements. A listing does not establish that a formulation can be dispensed. Delivery details are confirmed individually.
What this page is based on
Questions, answered
How much does this combination cost?
$231.90 per month plus the visit fee. Office and telehealth visits are $100. Your provider confirms the formulation, quantity, and any other costs before treatment.
Is this the same as Tesamorelin / Ipamorelin?
No. This listing includes MOTS-C as a third ingredient and has a separate price. Do not assume the two formulations have the same instructions or expected effects.
Is it proven for weight loss or muscle gain?
Research on the ingredients does not establish those benefits for this combination. Tesamorelin's approved indication is specific to HIV-associated lipodystrophy; it is not a general weight-loss approval.
What are the safety considerations?
Potential risks and monitoring depend on the exact formulation and your history. FDA has raised safety concerns about compounded ipamorelin and MOTS-C. Your provider should explain those uncertainties, relevant lab monitoring, and alternatives.
Start with a consult
$100 consultations, same day and next day in most cases.